MedTrace Logo

Nicotinic Acid in Hemodialysis Patients With Hyperphosphatemia

NCT02836184 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2016-08-30

No results posted yet for this study

Summary

With calcium carbonate as the positive control drug, to observe the effectiveness and safety of nicotinic acid in hemodialysis patients with hyperphosphatemia

Conditions

  • Hyperphosphatemia

Interventions

DRUG

Nicotinic Acids

Nicotinic acids is administered at an initial dosage of 50mg four times daily in the first week. If no significant side effects detected, the dosage will be titrated to 100mg five times daily within the second week and last to the end of study.

DRUG

Calcium Carbonate

Calcium Carbonate 500mg per oral, twice a day

Sponsors & Collaborators

  • Jiujiang No.1 People's Hospital

    lead OTHER

Principal Investigators

  • Xiaoran Feng, MD,PHD · Department of Nephrology, Jiujiang NO.1 People's Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-07-31
Primary Completion
2016-09-30
Completion
2016-09-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02836184 on ClinicalTrials.gov